118 related articles for article (PubMed ID: 28664723)
21. Improving the Hsp90 Inhibitors Containing 4-(2,4-Dihydroxyphenyl)-1,2,3-thiadiazole Scaffold: Synthesis, Affinity and Effect on Cancer Cells.
Kazlauskas E; Brukstus A; Petrikas H; Petrikaite V; Cikotiene I; Matulis D
Anticancer Agents Med Chem; 2017 Nov; 17(11):1593-1603. PubMed ID: 28270068
[TBL] [Abstract][Full Text] [Related]
22. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
[TBL] [Abstract][Full Text] [Related]
23. Peptide-Mediated Delivery of Chemical Probes and Therapeutics to Mitochondria.
Jean SR; Ahmed M; Lei EK; Wisnovsky SP; Kelley SO
Acc Chem Res; 2016 Sep; 49(9):1893-902. PubMed ID: 27529125
[TBL] [Abstract][Full Text] [Related]
24. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
[TBL] [Abstract][Full Text] [Related]
25. Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro.
Epp-Ducharme B; Dunne M; Fan L; Evans JC; Ahmed L; Bannigan P; Allen C
Sci Rep; 2021 May; 11(1):11103. PubMed ID: 34045581
[TBL] [Abstract][Full Text] [Related]
26. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.
Lee DH; Sung KS; Bartlett DL; Kwon YT; Lee YJ
Cell Signal; 2015 Feb; 27(2):293-305. PubMed ID: 25446253
[TBL] [Abstract][Full Text] [Related]
27. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
Brough PA; Aherne W; Barril X; Borgognoni J; Boxall K; Cansfield JE; Cheung KM; Collins I; Davies NG; Drysdale MJ; Dymock B; Eccles SA; Finch H; Fink A; Hayes A; Howes R; Hubbard RE; James K; Jordan AM; Lockie A; Martins V; Massey A; Matthews TP; McDonald E; Northfield CJ; Pearl LH; Prodromou C; Ray S; Raynaud FI; Roughley SD; Sharp SY; Surgenor A; Walmsley DL; Webb P; Wood M; Workman P; Wright L
J Med Chem; 2008 Jan; 51(2):196-218. PubMed ID: 18020435
[TBL] [Abstract][Full Text] [Related]
28. Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer.
Bao XH; Takaoka M; Hao HF; Fukazawa T; Yamatsuji T; Sakurama K; Takigawa N; Nakajima M; Fujiwara T; Naomoto Y
Oncol Rep; 2013 Jan; 29(1):45-50. PubMed ID: 23064324
[TBL] [Abstract][Full Text] [Related]
29. Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90.
Baruchello R; Simoni D; Grisolia G; Barbato G; Marchetti P; Rondanin R; Mangiola S; Giannini G; Brunetti T; Alloatti D; Gallo G; Ciacci A; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Guglielmi MB; Barbarino M; Foderà R; Pisano C; Cabri W
J Med Chem; 2011 Dec; 54(24):8592-604. PubMed ID: 22066525
[TBL] [Abstract][Full Text] [Related]
30. Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90).
Brasca MG; Mantegani S; Amboldi N; Bindi S; Caronni D; Casale E; Ceccarelli W; Colombo N; De Ponti A; Donati D; Ermoli A; Fachin G; Felder ER; Ferguson RD; Fiorelli C; Guanci M; Isacchi A; Pesenti E; Polucci P; Riceputi L; Sola F; Visco C; Zuccotto F; Fogliatto G
Bioorg Med Chem; 2013 Nov; 21(22):7047-63. PubMed ID: 24100158
[TBL] [Abstract][Full Text] [Related]
31. Mitochondria-penetrating peptides: sequence effects and model cargo transport.
Yousif LF; Stewart KM; Horton KL; Kelley SO
Chembiochem; 2009 Aug; 10(12):2081-8. PubMed ID: 19670199
[TBL] [Abstract][Full Text] [Related]
32. Heat shock protein 90: inhibitors in clinical trials.
Biamonte MA; Van de Water R; Arndt JW; Scannevin RH; Perret D; Lee WC
J Med Chem; 2010 Jan; 53(1):3-17. PubMed ID: 20055425
[No Abstract] [Full Text] [Related]
33. Non-Peptidic Cell-Penetrating Motifs for Mitochondrion-Specific Cargo Delivery.
Appiah Kubi G; Qian Z; Amiar S; Sahni A; Stahelin RV; Pei D
Angew Chem Int Ed Engl; 2018 Dec; 57(52):17183-17188. PubMed ID: 30376611
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
Taddei M; Ferrini S; Giannotti L; Corsi M; Manetti F; Giannini G; Vesci L; Milazzo FM; Alloatti D; Guglielmi MB; Castorina M; Cervoni ML; Barbarino M; Foderà R; Carollo V; Pisano C; Armaroli S; Cabri W
J Med Chem; 2014 Mar; 57(6):2258-74. PubMed ID: 24588105
[TBL] [Abstract][Full Text] [Related]
35. Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922.
Bergstrom M; Monazzam A; Razifar P; Ide S; Josephsson R; Langstrom B
J Nucl Med; 2008 Jul; 49(7):1204-10. PubMed ID: 18552146
[TBL] [Abstract][Full Text] [Related]
36. Hitting a Moving Target: How Does an N-Methyl Group Impact Biological Activity?
Koay YC; Richardson NL; Zaiter SS; Kho J; Nguyen SY; Tran DH; Lee KW; Buckton LK; McAlpine SR
ChemMedChem; 2016 Apr; 11(8):881-92. PubMed ID: 26805515
[TBL] [Abstract][Full Text] [Related]
37. Fluorescent dyes alter intracellular targeting and function of cell-penetrating tetrapeptides.
Szeto HH; Schiller PW; Zhao K; Luo G
FASEB J; 2005 Jan; 19(1):118-20. PubMed ID: 15489247
[TBL] [Abstract][Full Text] [Related]
38. Mitochondrial-targeted penetrating peptide delivery for cancer therapy.
Wu J; Li J; Wang H; Liu CB
Expert Opin Drug Deliv; 2018 Oct; 15(10):951-964. PubMed ID: 30173542
[TBL] [Abstract][Full Text] [Related]
39. The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-κB and disruption of mitochondria-dependent pathways.
Wang R; Shao F; Liu Z; Zhang J; Wang S; Liu J; Liu H; Chen H; Liu K; Xia M; Wang Y
Chem Biol Interact; 2013 Sep; 205(1):1-10. PubMed ID: 23777986
[TBL] [Abstract][Full Text] [Related]
40. BJ-B11, a novel Hsp90 inhibitor, induces apoptosis in human chronic myeloid leukemia K562 cells through the mitochondria-dependent pathway.
Ju HQ; Wang SX; Xiang YF; Liu Z; Liu JY; Chen ZP; Zeng FL; Xia M; Liu ZH; Xing GW; Wang SY; Wang YF
Eur J Pharmacol; 2011 Sep; 666(1-3):26-34. PubMed ID: 21620825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
